(Q43598640)

25 November 2017

title

Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group). (English)

1 reference

25 November 2017

main subject

phase II clinical trial

0 references

1 reference

Beate Schultheis

1

1 reference

25 November 2017

Dirk Strumberg

2

1 reference

25 November 2017

Lothar Bergmann

3

1 reference

25 November 2017

Ullrich Graeven

4

1 reference

25 November 2017

Axel-Rainer Hanauske

5

1 reference

25 November 2017

Rainer Lipp

6

1 reference

25 November 2017

Jochen Schuette

7

1 reference

25 November 2017

K Saito

8

1 reference

25 November 2017

Paul Scigalla

9

1 reference

25 November 2017

Max E Scheulen

10

1 reference

25 November 2017

publication date

12 April 2011

1 reference

Investigational New Drugs

25 November 2017

published in

1 reference

25 November 2017

volume

30

1 reference

25 November 2017

issue

3

1 reference

25 November 2017

page(s)

1184-1192

1 reference

25 November 2017

cites work

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9665-X

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9665-X

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9665-X

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9665-X

Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9665-X

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9665-X

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9665-X

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9665-X

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9665-X

A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9665-X

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9665-X

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9665-X

High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9665-X

An early phase II study of S-1 in patients with metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9665-X

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9665-X

A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9665-X

S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9665-X

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9665-X

Phase II trial of S-1 in combination with gemcitabine for chemo-naïve patients with locally advanced or metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9665-X

A pilot study for combination chemotherapy using gemcitabine and S-1 for advanced pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9665-X

A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9665-X

Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9665-X

CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9665-X

Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer

21 January 2018

1 reference

12 December 2020

Phenotypic CYP2A6 variation and the risk of pancreatic cancer

1 reference

12 December 2020

Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale

1 reference

12 December 2020

Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators

1 reference

12 December 2020

Pretreatment with S-1, an oral derivative of 5-fluorouracil, enhances gemcitabine effects in pancreatic cancer xenografts.

1 reference

12 December 2020

A late phase II study of S-1 for metastatic pancreatic cancer

1 reference

12 December 2020

Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer

1 reference

12 December 2020

Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer

1 reference

12 December 2020

10.1007/S10637-011-9665-X

Identifiers

DOI

1 reference

Dimensions Publication ID

25 November 2017

1045928711

0 references

1 reference